Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.

Rhea-AI Summary

Insulet (NASDAQ: PODD) announced that its Omnipod 5 Automated Insulin Delivery System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring sensor in the U.S. This integration makes Omnipod 5 the most connected tubeless AID system in the U.S. and the only AID system indicated for both type 1 and type 2 diabetes. The Omnipod 5 System automatically adjusts insulin delivery every five minutes using SmartAdjust technology, eliminating the need for multiple daily injections while improving diabetes management outcomes.

Positive

• First tubeless AID system compatible with multiple CGM sensors in the U.S.
• Only AID system approved for both type 1 and type 2 diabetes
• Ranked as #1 prescribed and favorite pump in the U.S.
• Expands market reach by integrating with widely-used FreeStyle Libre 2 Plus sensor

Negative

• None.

Insights

Medical Device Industry Analyst

The integration of Omnipod 5 with Abbott's FreeStyle Libre 2 Plus sensor marks a significant market expansion opportunity for Insulet. This compatibility makes Omnipod 5 the most connected tubeless automated insulin delivery system in the U.S., potentially capturing a larger share of the 14 billion diabetes device market.

The strategic partnership strengthens Insulet's competitive position against rivals like Medtronic and Tandem. With Omnipod 5 already being the top prescribed pump in the U.S., this integration could accelerate adoption rates among both Type 1 and Type 2 diabetes patients who prefer Abbott's widely-used CGM system. The expanded compatibility reduces barriers to entry for new users and could drive substantial revenue growth through increased device sales and recurring Pod purchases.

Healthcare Technology Specialist

This technological advancement represents a important step in automated insulin delivery systems. The integration enables more sophisticated diabetes management through real-time data sharing between the CGM and pump, offering automated insulin adjustments every five minutes. The system's ability to proactively correct high glucose levels while preventing lows demonstrates advanced algorithm capabilities that could reduce complications and improve patient outcomes.

The smartphone control feature and waterproof design address key user experience factors that drive adoption. This user-centric approach, combined with the elimination of daily injections and fingersticks, positions Insulet favorably in the growing digital health sector where convenience and connectivity are paramount.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S.

“We are excited to announce that Omnipod 5, the only AID system indicated for both type 1 and type 2 diabetes, is now integrated with Abbott’s FreeStyle Libre 2 Plus sensor in the U.S. This latest innovation will allow millions of Americans who take insulin the ability to get started on Pod therapy using their preferred CGM sensor,” said Eric Benjamin, Insulet’s Executive Vice President and Chief Product and Customer Experience Officer. “As we work to reach more people with our innovative, tubeless Omnipod 5 AID System, today’s announcement represents yet another significant step forward for our Company and our customers.”

The Omnipod 5 System simplifies diabetes management and has shown to improve results by eliminating the need for multiple daily injections (MDI) therapy and automatically adjusting insulin delivery every five minutes using its advanced SmartAdjust^TM technology. As the number one prescribed and number one favorite pump¹ in the U.S., the waterproof², discreet, and wearable Omnipod 5 is the first tubeless AID system that communicates with a CGM, proactively correcting for highs and helping to protect against lows, day and night^3,4,5.

Omnipod 5 user John Rowley, who lives in the United Kingdom where the FreeStyle Libre 2 Plus sensor integration launched earlier this year, had been using MDI for 36 years before making the switch to Pod therapy.

“Having spent more than half my life injecting myself with insulin, Omnipod 5 with its connection to my FreeStyle Libre 2 Plus sensor has been truly liberating. When you have diabetes, there is so much more to think about when it comes to daily life,” said Mr. Rowley. “Omnipod 5 has made my life so much simpler, with much less to carry around with me, and less to worry about overall.”

For more information on how to access Omnipod 5 with the FreeStyle Libre 2 Plus sensor, visit Omnipod.com.

1USA 2023, data on file.

2The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod 5 Controller is not waterproof.

3Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

4Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

5Pasquel FJ, et al. Presented at: ADA; June 21-24, 2024; Orlando, FL. Study in 305 people with type 2 diabetes participants with T2D aged 18-75 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod and SmartAdjust are trademarks or registered trademarks of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241120268759/en/

Investor Relations:

June Lazaroff

Senior Director, Investor Relations

(978) 600-7718

jlazaroff@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

What new integration was announced for Insulet's Omnipod 5 (PODD) in 2024?

Insulet announced that its Omnipod 5 Automated Insulin Delivery System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring sensor in the U.S.

What makes Insulet's Omnipod 5 (PODD) unique in the diabetes management market?

Omnipod 5 is the only AID system indicated for both type 1 and type 2 diabetes, and is now the most connected tubeless automated insulin delivery system in the U.S.

How often does the Omnipod 5 (PODD) system adjust insulin delivery?

The Omnipod 5 System automatically adjusts insulin delivery every five minutes using its SmartAdjust technology.